Boryung Biopharama Co.

Company Description

Boryung Biopharama Co. was first established as Boryung Pharmaceutics Inc.in April 26th, 1991.  Boryung Biopharama Co. aim was to develop and to sell biological products that were receiving spotlights as the future of pharmaceutical industry.

Initially, Biopharma concentrated in preventive medicinal business such as vaccines, and invested and researched appropriately.As a result, we developed the first domestic oral vaccines for typhoid.

Our vaccine formula is now patented in 12 countries, including Korea, the United States, Japan, and England which is also contributing to domestic export.

From the initial stage, Boryung Biopharma has been recognized as an eligible KGMP manufacturer of all dosage forms of medicine and injections from the Ministry of Health and Welfare therefore we have been manufacturing and selling superior quality medical supplies.

In addition, our excellent marketing strategies made us a major corporation in the domestic preventative medicinal market, and we are going to achieve continuous growth by pioneering the export market in Southeast Asia, South
America, Africa, and more.

In April 26th, 2002, Boryung Pharmaceutics Inc. celebrated our 11th anniversary,and changed the company name to Boryung Biopharma Co., and drawing from our experience and accomplishments in preventative medicine, we started to lay a new foundation in the biotechnology industry, which is a promise for a brighter future.

In July 1st, 2003, we established "Boryung i-Mom Cell", which stores umbilical cord blood (UCB) cells for 15 years using the latest freezing storage. This feat was possible only from our constant efforts to establish a close cooperative system with our affiliate UCB cell provision bank.  

Thanks to the establishment of UCB cell bank,